08:31 AM EDT, 09/16/2025 (MT Newswires) -- Jyong Biotech ( MENS ) said Tuesday it has completed patient enrollment in its phase II clinical trial of MCS-8, an investigational drug candidate for prostate cancer prevention.

Over 700 high-risk subjects have been enrolled in the clinical trial, the company said.

The randomized, placebo-controlled trial is being conducted across 20 hospitals in Taiwan, with the participation of over 130 urologists, Jyong Biotech ( MENS ) said.

Shares were up 2.8% in recent premarket activity.